Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CPI-300 in advanced solid tumors
NCT04808453Phase 1Completed
- Sponsor
- Coordination Pharmaceuticals, Inc.
- Start
- Jun 2021
- Primary completion
- Dec 2023
- Modality
- Nanoparticles, Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of CPI-300 in solid tumor (advanced stage), sponsored by Coordination Pharmaceuticals, Inc. Primary endpoint: Adverse Events (DLT) at 28 days. Started Jun 2021; status: completed.
02
Drugs
CPI-300
03
Conditions
solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT04808453.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04808453.